Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
10 May 2021

Telix begins Phase III prostate cancer treatment trial

Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant prostate cancer (mCRPC) patients. The trial initiation comes after approval…